淫羊藿叶的活性代谢物通过减轻线粒体功能障碍促进APP/PS1小鼠海马神经发生

The active metabolite of Epimedii Folium promotes hippocampal neurogenesis in APP/PS1 mice by alleviating mitochondrial dysfunction.

作者信息Jia-Ming Bai, Tong Li, Xue Di, Jing-Xian Yang, Zhao-Qi Cui, Dong-Yu Min, Yu-Feng Shen, Si-Yu Shan, Ye-Xin Zhang, Yi-Jun Shi, Zhi-Li Xu, De-Qiang Dou, Hong-He Xiao
PMID40351431
发布时间2025-04-16
DOI10.3389/fphar.2025.1546256

实验完整度

体外APP-NSCs模型筛选、线粒体功能检测、体内APP/PS1小鼠行为学、组织学、神经发生及机制验证,并使用线粒体抑制剂Rotenone进行功能验证,证据层级丰富。

主要模型

APP-NSCs(过表达APPswe的神经干细胞) 6月龄雄性APP/PS1转基因小鼠 C57BL/6J小鼠(正常对照)

重点核对

APP-NSCs细胞模型:过表达APPswe的神经干细胞 药物浓度:ICS II 0.25、0.5、1 μM处理24小时 体内剂量:ICS II 10 mg/kg口服灌胃,Rotenone 2.5 mg/kg腹腔注射,持续49天 EdU标记:100 mg/kg腹腔注射,在治疗第4周进行 分组:APP/PS1小鼠分5组(Model、ICS II、Rot、ICS II+Rot、Normal Control),每组10只

摘要

Introduction: Alzheimer's disease (AD), the most common form of dementia, currently has no effective cure. Epimedii Folium (EF), a traditional Chinese medicine known as Yin-yang-huo, has demonstrated significant neuroprotective properties.Methods: In this study, neural stem cells overexpressing the APPswe gene (APP-NSCs) were used as an in vitro AD model. The CCK-8, LDH, neurosphere formation, and BrdU incorporation assays were employed to identify the most effective bioactive metabolite of EF in promoting NSC proliferation. Subsequently, JC-1 staining, ATP quantification, and ROS assays were conducted to evaluate the protective effects of Icariside II (ICS II)-identified as the most effective metabolite-on mitochondrial function. APP/PS1 transgenic mice received an oral administration of 10 mg/kg ICS II for 7 weeks. Cognitive function was assessed using the Morris water maze and nest-building tests, while H&E and Nissl staining were used to evaluate brain tissue pathology. Transmission electron microscopy (TEM) examined the ultrastructural integrity of hippocampal neurons, immunofluorescence assessed hippocampal neurogenesis, and Western blotting quantified proteins involved in mitochondrial dynamics. Additionally, Rotenone (Rot), a mitochondrial respiratory chain inhibitor, was applied to disrupt mitochondrial function, allowing an evaluation of whether the neurogenesis-promoting effect of ICS II depends on maintaining mitochondrial structure and function.Results and discussion: The results demonstrated that ICS II exhibited the strongest capacity to promote APP-NSC proliferation (P < 0.01, η2 = 0.845), followed by Icariin and Icaritin. ICS II treatment significantly ameliorated cognitive deficits (P < 0.01, η2 = 0.883), neuronal damage, and impairments in neurogenesis in adult APP/PS1 mice. Moreover, ICS II rescued mitochondrial damage by upregulating fusion proteins (Mfn1 and Mfn2) and downregulating fission proteins (p-Drp1/Drp1 and Mff); however, these protective effects were negated by Rot administration. In conclusion, this study identifies ICS II as one of the most effective metabolites of EF, promoting hippocampal neurogenesis and alleviating mitochondrial dysfunction in APP/PS1 mice, thereby offering promising therapeutic potential for AD.

实验结论

提炼研究问题、关键发现与证据,快速把握文章的核心贡献。

研究问题
评估淫羊藿叶的八种活性代谢物中哪种最能促进神经干细胞增殖,并探讨其主要代谢物ICS II通过何种机制改善APP/PS1小鼠的认知功能。
核心机制
ICS II通过上调线粒体融合蛋白Mfn1和Mfn2,下调分裂蛋白p-Drp1/Drp1和Mff,缓解线粒体功能障碍,从而促进海马神经发生。
主要证据
体外实验显示ICS II显著提高APP-NSCs的增殖和线粒体功能;体内实验显示ICS II改善APP/PS1小鼠认知功能、减轻神经元损伤、增加EdU+/Sox-2+和EdU+/NeuN+细胞数量,并调节线粒体动力学相关蛋白表达。
研究意义
该研究为ICS II作为AD治疗候选药物提供实验依据,指出通过调节线粒体动力学促进神经发生可能是AD的潜在治疗策略。

研究路径

按研究推进顺序梳理实验设计、验证步骤与关键观察。

1

体外药物筛选

筛选EF的八种活性代谢物中促进APP-NSCs存活和增殖的最有效成分。

将APP-NSCs暴露于八种代谢物(ICS II、ICA、Epimedin A、Epimedin B、Epimedin C、Icaritin、Anhydroicaritin、ICS I)0.25、0.5、1 μM处理24小时,CCK-8检测细胞活力,LDH检测细胞损伤。

2

体外增殖验证

验证筛选出的有效代谢物ICS II、ICA和Icaritin对APP-NSCs增殖的影响。

用1 μM ICS II、ICA、Icaritin处理APP-NSCs 7天,进行神经球形成实验和BrdU掺入实验,评估细胞增殖能力。

3

体外线粒体功能评估

评估ICS II对APP-NSCs线粒体功能的保护作用。

将GFP-NSCs和APP-NSCs分为四组,用1 μM ICS II处理24小时,进行JC-1染色、ATP含量和ROS水平检测。

4

动物实验干预

评估ICS II对APP/PS1小鼠认知功能、海马神经发生和线粒体功能的影响。

6月龄雄性APP/PS1小鼠分为5组,ICS II组口服10 mg/kg,Rot组腹腔注射2.5 mg/kg,ICS II+Rot组联合给药,持续49天。第4周腹腔注射EdU标记增殖细胞。行为学测试(MWM和巢穴构建)后取脑组织进行组织学、免疫荧光、TEM和Western blot检测。

5

机制验证

验证ICS II的神经发生促进作用是否依赖于线粒体功能的完整性。

通过给予Rotenone抑制线粒体呼吸链,观察ICS II的各项效应是否被阻断。

研究方法

按研究目的归类文中使用的方法,便于定位所需技术。

产品清单

实验环节名称品牌货号
淫羊藿次苷IIWeikeqi Biotech--
B27添加剂Gibco17,054-044
0.25%胰蛋白酶Gibco25,200,056
DMEM/F12培养基Gibco--
表皮生长因子PeproTech315-09
碱性成纤维细胞生长因子PeproTech100-18B
青霉素/链霉素HycloneJ19007
溴脱氧尿苷Meilun BiotechMB3126-2
细胞计数试剂盒-8Nanjing Jiancheng--
乳酸脱氢酶试剂盒Nanjing Jiancheng--
JC-1试剂盒Biosynthesis Biotech--
乙炔基脱氧尿苷Sigma-Aldrich61135-33-9
DAPIBeyotime BiotechnologyC1005
抗Sox-2抗体Proteintech20118-1-AP
抗NeuN抗体Proteintech26975-1-AP
抗Mfn1抗体Biosynthesis Biotechbs-0557R
抗Mfn2抗体Biosynthesis Biotechbs-2988R
抗Mff抗体Biosynthesis Biotechbs-7628R
抗Drp1抗体Biosynthesis Biotechbs-4100R
抗p-Ser616-Drp1抗体Biosynthesis Biotechbs-12702R
抗GAPDH抗体Wanlei BiotechWL01114
山羊抗兔IgG(Alexa Fluor 488)Jackson ImmunoResearch159082
鱼藤酮Aladdin文中未明确说明
Cell-Light Apollo 567染色试剂盒RiboBioC10371-1
羧甲基纤维素钠----

关键环节

汇总复现实验时建议重点确认的条件及原文阅读提示。

环节核对要点
体外细胞筛选
APP-NSCs细胞模型,处理浓度和时间,细胞密度
阅读提示:见Methods 2.2-2.5,Figure 1 legend
线粒体功能检测
JC-1染色分组、ICS II浓度、处理时间
阅读提示:见Methods 2.6-2.8,Figure 3 legend
动物分组与给药
动物品系、月龄、性别、给药剂量和途径、持续时间、分组设计
阅读提示:见Methods 2.9,Figure 4-8 legends
认知行为学评估
MWM测试参数、巢穴构建评分标准
阅读提示:见Methods 2.10-2.11,Figure 4 legend
神经发生检测
EdU标记时间、免疫荧光抗体浓度、Sox-2和NeuN标记条件
阅读提示:见Methods 2.13,Figure 6-7 legends
线粒体形态学检查
TEM样品制备、观察指标
阅读提示:见Methods 2.14,Figure 8 legend
蛋白表达检测
抗体稀释比例、蛋白提取方法
阅读提示:见Methods 2.15,Figure 8 legend